Navigation Links
New discovery reveals fate of nanoparticles in human cells
Date:9/22/2009

Scientists funded by the Biotechnology and Biological Sciences Research Council (BBSRC) have uncovered what happens to biomimetic nanoparticles when they enter human cells. They found that the important proteins that make up the outer layer of these nanoparticles are degraded by an enzyme called cathepsin L. Scientists now have to take this phenomenon into account and overcome this process to ensure the exciting field of nanomedicine can progress. The research is published today (22 September) in ACS Nano.

Dr Raphal Lvy, a BBSRC David Phillips Fellow at the University of Liverpool and lead researcher on the project said: "We've known for some time that nanoparticles are taken into cells and there have been experiments done to establish their final destinations, but we didn't know until now what state they are in by the time they get there."

In most biological applications, nanoparticles are coated with a layer of molecules, often proteins, which determine the use of nanoparticles when they enter cells. The researchers have confirmed, in a wide range of cells, that nanoparticles are taken into a region called the endosome, where this essential coating is degraded by cathepsin L.

Dr Violaine Se, also a BBSRC David Phillips Fellow at the University of Liverpool, and joint corresponding author, added: "One of the promising applications of nanoparticles in medicine is to use them as a method to deliver therapeutic protein molecules inside cells. For these biological therapies to be effective the proteins have to be maintained with high integrity and unfortunately we have seen this compromised by the degrading action of cathepsin L."

The design of any intracellular nanodevice must now take into account the possibility of cathepsin L degradation and either bypass the endosome area all together or have some built-in inhibition of the enzyme.

Dr Lvy continued: "The methods we have developed will help with this as we
'/>"/>

Contact: Nancy Mendoza
press.office@bbsrc.ac.uk
44-179-341-3355
Biotechnology and Biological Sciences Research Council
Source:Eurekalert

Page: 1 2

Related biology technology :

1. Antigen Discovery, Inc. Awarded Grant for Chlamydia Vaccine Development
2. CELLECTA, INC. to Develop New Approach for Cancer Gene Discovery in Partnership with Roswell Park Cancer Institute and Health Research, Inc.
3. StoredIQ Shares Expertise at IQPCs eDiscovery Pharma, Biotech and Medical Device Conference
4. Alzheimers Drug Discovery Foundation and the Lewy Body Dementia Association Invite Scientists to Apply for LBD Grant Award Program
5. PTC Therapeutics Announces Celgene Exercised Option to Drug Discovery Collaboration
6. PTC Therapeutics Announces Drug Discovery Collaboration With Roche
7. ChemBridge Corporation and Collaborative Drug Discovery Announce Strategic Collaboration to Provide Diverse Chemical Libraries Together With Researchers Own Private Data
8. Alzheimers Drug Discovery Foundation Hosts 10th International Conference on Alzheimers Drug Discovery - September 14-15
9. Rib-X Pharmaceuticals Antibiotic Drug Discovery Platform Discovers Novel Compounds with Activity Against Key Multiple Drug Resistant Gram-negative Bacteria
10. Discovery of natural odors could help develop mosquito repellents
11. PharmatrophiX, Initially Funded by the Alzheimers Drug Discovery Foundation, Announces Exclusive Global Collaboration with Elan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Reports from CDC show approximately 117 ... or more chronic health conditions - including cardiovascular disease, ... of these diseases, but may not eliminate the severe ... implanted nerve stimulation devices today offer relief, they require ... induce side effects. , To eliminate the need ...
(Date:12/19/2014)... With only 2 weeks left of 2014, ... Biohit products . The product specials include Buy 1 ... Trade-in Program, and free pipette tips. , Sartorius mLINE ... world. They are ideal for lab technicians performing long ... ,     Full volume range of 0.1 uL to 10 ...
(Date:12/19/2014)... , Dec. 18, 2014 Relmada Therapeutics, Inc. ... the treatment of chronic pain, announced the results of ... "This was a transformational year in Relmada,s history ... for our company," said Sergio Traversa , chief ... have executed on key financial, human resource and clinical ...
(Date:12/17/2014)... Achim Noack has been named global vice president ... position, Noack will assist Jerry Stoller, CEO and president ... and supervise global marketing management and implementation of new ... and experience in the crop protection industry,” says Jerry ... thinking will be a great asset for Stoller Group, ...
Breaking Biology Technology:Draper Wins GSK Funding for Smaller, Smarter Implantable Devices 2Major Pipette Distributor Pipette.com Announces Sartorius Year End Specials 2Relmada Therapeutics Announces Results of Annual Shareholders Meeting 2Achim Noack Joins Stoller Group as Global Vice President of Marketing and Administration 2
... BARCELONA, Spain , June 14 Data ... in Barcelona , highlights the impact of febrile ... patients. The IMPACT NHL study showed that unplanned hospitalisations, ... to suboptimal relative dose intensity (RDI) of chemotherapy were ...
... ... Mogil, an internationally-renowned leader in pain research, will be presenting “What’s Wrong with ... be held October 4-5, 2010 in Philadelphia, Pennsylvania. , ... Minneapolis, MN (PRWEB) June 10, ...
... ... oldest buildings on earth and a “fascinatingly weird” ancient culture. , ... (PRWEB) June 11, 2010 -- U.S. nonprofit The ... a simple introduction to megalithic architects in Frequently Asked Question format. With content drawn ...
Cached Biology Technology:New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 2New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 3New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 4New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 5New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 6New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 7New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 8New Data Confirms the Negative Impact of Febrile Neutropenia in Patients With Non-Hodgkin Lymphoma Receiving R-CHOP Chemotherapy 9Jeffrey Mogil to Speak on Animal Models of Pain at Arrowhead's 4th Annual Pain Therapeutics Summit 2New tool for exploring the ancient world. 2
(Date:12/17/2014)... -- Valencell, a leader in performance biometric data sensor ... leaders such as Intel, Jabra, Atlas, and Scosche to ... These products will be showcased at CES 2015, taking ... . "Our partners choose PerformTek biometrics, ... with the clinical data to back it up," said ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here ... account but can,t remember your password, site key or the ... was your first grade teacher? Today, ... the app that will finally put an end to ... 1U TM . 1U leverages a user,s smartphone ...
Breaking Biology News(10 mins):Valencell PerformTek Biometrics Power the Most Accurate Wearables at CES 2015 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3
... recently published their joint findings that fatal prion diseases, which ... Findings published this month in the peer-reviewed journal, ... to seven months before an animal shows physical signs of ... brain was being eradicated. This member of the prion family ...
... have demonstrated, for the first time, a graphene-based ... cells and capable of recording the electrical signals ... for further investigation of a promising new material. ... leading contender for future biomedical applications requiring a ...
... Take a Petri dish containing crude petroleum and it ... make up the fossil fuel. Sprinkle mushroom spores over the ... an incubator, and surprise, the petroleum and its smell will ... professor of biological sciences and researcher at the University of ...
Cached Biology News:Medical researchers in Canada and the US discover hidden side of prion diseases 2Biocompatible graphene transistor array reads cellular signals 2Biocompatible graphene transistor array reads cellular signals 3Petroleum-eating mushrooms 2Petroleum-eating mushrooms 3Petroleum-eating mushrooms 4
... suit the widest possible range of sample ... Labware carriers can be placed at any ... for the user, thanks to a numbered ... guided into position. This allows easy removal ...
... Sac-Cel (Second Antibody Coated CELlulose) was developed ... of Dartford, Kent, one of the earliest ... IDS acquired the product range in 1987. ... clinical biochemists developing their own "in house" ...
... N,N- bis- (3-D-Gluconamidopropyl)deoxycholamide ... analog of CHAPS and CHAPSO. Has reduced ... anion exchange chromatography on DEAE-cellulose. Aggregation number: ... Soluble in H 2 O. Aggregation number ...
... N-Dodecyl-N,N-(dimethylammonio)butyrate White crystalline solid. ... to DDMAU (Cat. No. 252005) but differing ... More efficient for the extraction of mycoplasma ... Purity: ≥98% by TLC. Soluble ...
Biology Products: